About AVT
Browse Articles
Authors
Customer Services

Current Issue

Displaying 12 results:

Free
Letter

Very late HCV relapse following triple therapy for hepatitis C

Pablo Barreiro, Eugenia Vispo, Ivana Maida, Antonio Aguilera, José V Fernández-Montero, Carmen de Mendoza, Pablo Labarga, Vincent Soriano

Antiviral Therapy 2014; 19:723-724


Free
Letter

The impact of wild-type reversion on transmitted resistance surveillance

David C Boettiger, Sasisopin Kiertiburanakul, Somnuek Sungkanuparph, Matthew G Law, the TREAT Asia Studies to Evaluate Resistance

Antiviral Therapy 2014; 19:719-722


Workshop report

Summary of presentations from the International Workshop on Antiviral Drug Resistance: Meeting the Global Challenge, 3–7 June 2014, Berlin, Germany

Neil Parkin

Antiviral Therapy 2014; 19:701-717


Short communication

Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: The CASTLE biomarker substudy

Graeme Moyle, Helene Hardy, Jonathan Uy, Neelanjana Ray, Maria Jesus Jimenez-Exposito, Donnie McGrath, Edwin DeJesus

Antiviral Therapy 2014; 19:693-699


Short communication

Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity

Rujuta A Bam, Stephen R Yant, Tomas Cihlar

Antiviral Therapy 2014; 19:687-692


Original article

Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor

David Nelson, Eric M Yoshida, Matthew S Paulson, Paul N Hengen, Dongliang Ge, Bittoo Kanwar, John McNally, Phillip S Pang, G Mani Subramanian, John G McHutchison, Petr Urbanek, Eric Lawitz, Thomas J Urban

Antiviral Therapy 2014; 19:679-686


Original article

Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors

Rujuta A Bam, Gabriel Birkus, Darius Babusis, Tomas Cihlar, Stephen R Yant

Antiviral Therapy 2014; 19:669-677


Original article

Amino acid sequence analysis in patients with chronic HCV genotype 1b infection during pegylated interferon-α2a and ribavirin therapy

Juan-Juan Fu, Wei-Jing Kong, Dong Jiang, Xiu-Cheng Pan, Lai Wei

Antiviral Therapy 2014; 19:661-668


Original article

Population pharmacokinetics of nevirapine in Thai HIV-infected patients

Thanaporn Wattanakul, Anchalee Avihingsanon, Weerawat Manosuthi, Baralee Punyawudho

Antiviral Therapy 2014; 19:651-660


Original article

Evaluation of protective efficacy of the synthetic peptide vaccine containing the T-helper 1 epitope with CpG oligodeoxynucleotide against feline infectious peritonitis virus infection in cats

Tomomi Takano, Keisuke Tomizawa, Hiroyuki Morioka, Tomoyoshi Doki, Tsutomu Hohdatsu

Antiviral Therapy 2014; 19:645-650


Page:
Copyright © Nucleus Global 2014. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.